{"disease":{"id":"atypical-lobular-hyperplasia","name":"atypical lobular hyperplasia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05868252","title":"Molecular Analysis of the Sloane Project","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"King's College London","has_results":false},{"nct_id":"NCT05178498","title":"Impact of Dietary Inflammatory Potential on Breast Cancer Risk","phase":"","overall_status":"RECRUITING","enrollment_count":960,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06184750","title":"Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07499999","title":"Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT02928978","title":"Ruxolitinib for Premalignant Breast Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Julie Nangia","has_results":false},{"nct_id":"NCT04570956","title":"Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":65,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05755269","title":"Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03323658","title":"Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}